Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Melio logo — Sequence profiling by AI powered DNA Melting

Melio

Sequence profiling by AI powered DNA Melting

Founded 2018 United States Santa Clara, United States 29 employees Seed Biotechnology, Health Care

General Information

Company Name Melio
Founded Year 2018
Location United States Santa Clara, United States
Employees 29
Industries Biotechnology, Health Care
Funding Stage Seed
Business Model B2B, Platform, SaaS
Revenue Model Usage Based, Subscription, Tiered Pricing
Social

BounceWatch is an independent company data service, not affiliated with Melio. To contact Melio, visit melio.tech.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Melio compare?

A PDF of Melio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Melio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Melio

Melio, founded in 2018, is a promising player in the Biotechnology and Health Care industries. Headquartered in the United States, the company's mission is encapsulated by its slogan: "Sequence profiling by AI powered DNA Melting."

The firm's focus is on developing a clinically actionable, rapid, and comprehensive test for detecting all common infections. This innovative approach leverages AI technology to enhance the precision and speed of DNA sequencing, potentially transforming the landscape of infection diagnostics.

Despite its potential, Melio has yet to receive investment at this point, as indicated by the absence of any documented last investment or investor involvement. This aspect may appeal to venture capitalists seeking ground-floor opportunities in the biotech space.

Services & Products

Rapid Pathogen Identification
Culture-Free Blood Testing
Comprehensive Pathogen Detection

Target Customers

Hospitals Healthcare Providers Neonatal Intensive Care Units Medical Laboratories

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Undisclosed 1
Lexi Ventures
Lexi Ventures
01 Jun 2024
Seed Undisclosed 2
SOSV indiebio
SOSV, indiebio
01 Aug 2022
Grant Undisclosed -
01 Jun 2020
Spinout Undisclosed 1
University Ventures
University Ventures
01 Jan 2018

Melio Alternatives & Competitors

View All Alternatives
Melio vs
Pattern Bioscience
Pattern Bioscience United States

Our mission is simple: We will improve the world's most important health decisions.

Series C
76 employees
Biotechnology, Health Care
Melio vs
Day Zero Diagnostics, Inc
Day Zero Diagnostics, Inc United States

The future of infectious disease diagnostics starts at Day Zero.

64 employees
Biotechnology, Health Care
Melio vs
Xagenic
Xagenic

Empowering clinicians with rapid, near-patient molecular testing for improved patient care and reduc...

Series B
Biotechnology, Health Care
View all alternatives

FAQ About Melio

Sequence profiling by AI powered DNA Melting
Melio was founded in 2018.
Melio is headquartered in Santa Clara, United States.
Melio operates in Biotechnology and Health Care. Its customers include Hospitals, Healthcare Providers and Neonatal Intensive Care Units.
Melio has a B2B, Platform and SaaS business model. Its revenue comes from Usage Based, Subscription and Tiered Pricing.
Melio has approximately 29 employees.
Melio has completed 4 funding rounds. The latest funding stage is Seed.
Melio offers: Rapid Pathogen Identification, Culture-Free Blood Testing, Comprehensive Pathogen Detection.
Top alternatives and competitors to Melio include Pattern Bioscience, Day Zero Diagnostics, Inc, Xagenic, Leuko, Digistain®. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Melio and Pattern Bioscience are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Melio, https://bouncewatch.com/company/melio-1, updated 19 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes